2Athanassiadou P, Grapsa D, Athanassiades P, et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer[ J]. Pathol Res Pract ,2008,204:241-249.
3Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy : fulfilled promises and open questions [ J ]. Carcinogenesis, 2007,28 : 1133 - 1139.
4Fortugno P, Wall NR, Giodini A, et al. survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function [J]. J Cell Sci ,2002,115:575- 585.
5Sampath J,Pelus I,M. Ahernative splice variants of survivin as potential targets in cancer[ J ]. Curt Drug Discov Technol,2007,4 : 174-191.
6Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants [ J ]. Cell Death Differ,2002,9 : 1334-1342.
8Ferrando-May E. Nucleocytoplasmic transport in apoptosis [ J ]. Cell Death Differ, 2005,12 : 1263-1276.
9Weis K. Regulating access to the genome :nucleocytoplasmic transport throughout the cell cycle[J]. Cell ,2003, 112:441- 451.
10Rodriguez JA, Lens SM, Span SW, et al. Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown [ J ]. Oncogene. 2006,25 : 4867-4879.
